Illumina’s (ILMN) “Equal Weight” Rating Reiterated at Morgan Stanley

Morgan Stanley reissued their equal weight rating on shares of Illumina (NASDAQ:ILMN) in a research report report published on Tuesday, MarketBeat.com reports. They currently have a $156.00 price target on the life sciences company’s stock.

Several other equities analysts have also recently issued reports on the company. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. StockNews.com assumed coverage on Illumina in a research note on Thursday, August 29th. They set a “buy” rating for the company. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Royal Bank of Canada boosted their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Finally, Barclays boosted their target price on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Stock Down 5.1 %

Shares of ILMN traded down $7.24 during midday trading on Tuesday, hitting $135.00. The company had a trading volume of 1,529,883 shares, compared to its average volume of 2,005,431. The company’s 50-day simple moving average is $139.44 and its 200-day simple moving average is $124.23. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The firm has a market capitalization of $21.41 billion, a P/E ratio of -13.76 and a beta of 1.13. Illumina has a 1 year low of $92.69 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 EPS. As a group, sell-side analysts expect that Illumina will post 4.11 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ILMN. Versant Capital Management Inc increased its holdings in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the period. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina in the second quarter valued at approximately $34,000. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new position in Illumina during the second quarter worth $61,000. Finally, Private Trust Co. NA grew its holdings in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.